Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 14/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242978 | 0.93 | CYP19A1 (0.61) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL2604717 | 0.84 | CYP19A1 (0.64) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL2070571 | 0.84 | CYP19A1 (0.61) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL19410272 | 0.81 | CYP19A1 (0.62) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL19410273 | 0.78 | CYP19A1 (0.55) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL3957591 | 0.77 | ALOX12 (0.53) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL154220 | 0.77 | ALOX12 (0.42) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL6143062 | 0.77 | CYP19A1 (0.63) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL131535 | 0.77 | ALOX12 (0.42) | CYP19A1ALOX12ALOX15KCNH2TRPV1 | |
| SCHEMBL5503331 | 0.77 | CYP19A1 (0.84) | CYP19A1ALOX12ALOX15KCNH2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | SHBG, OAT, APOB | CYP19A1 16/4885ALOX12 1633/4885ALOX15 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.